3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Rhabdoid Tumor
1
Neoplasms
1
Colorectal Neoplasms
1
Chordoma
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Advanced Liver Cancers
1
Interventions
pembrolizumab
20
Bevacizumab
14
Carboplatin
12
Standard of Care
10
Nivolumab
9
Cyclophosphamide
9
Cetuximab
8
Pemetrexed
7
Exercise
7
Doxorubicin
7
durvalumab
6
atezolizumab
6
Temozolomide
6
Radiotherapy
6
Prednisone
6
Paclitaxel
6
Cisplatin
6
Blood Specimen Collection
6
abemaciclib
5
Fluorouracil
5
130-nm albumin-bound paclitaxel
5
olaparib
4
dostarlimab
4
Rituximab
4
Leucovorin
4
Gemcitabine
4
Fulvestrant
4
Docetaxel
4
Dexamethasone
4
venetoclax
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Tiragolumab
×
30 days
×
Clear all
NCT05862285
2026-05-12
UmbrellaMAX
Hoffmann-La Roche
Phase 3
Recruiting
100 enrolled